Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses EXEL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EXEL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Morrissey | $1,306,040 | $0 | $30,539,552 | $0 | $1,382,591 | $0 | $11,000 | $33,239,183 |
| President and Chief Executive Officer | ||||||||
| Amy Peterson | 614,496 | 0 | 8,442,574 | 0 | 0 | 0 | 2,088,964 | 11,146,034 |
| Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer | ||||||||
| Christopher Senner | 822,823 | 0 | 9,343,867 | 0 | 470,782 | 0 | 11,000 | 10,648,472 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Dana Aftab | 659,058 | 0 | 9,479,940 | 0 | 397,250 | 0 | 11,000 | 10,547,248 |
| Executive Vice President, Research and Development | ||||||||
| Patrick Haley | 621,321 | 0 | 8,061,792 | 0 | 327,303 | 0 | 11,000 | 9,021,416 |
| Executive Vice President, Commercial | ||||||||
| Jeffrey Hessekiel | 672,374 | 0 | 8,309,218 | 0 | 0 | 0 | 11,000 | 8,992,592 |
| Former Executive Vice President and General Counsel | ||||||||
| Brenda Hefti | 454,545 | 0 | 3,451,975 | 0 | 286,751 | 0 | 11,000 | 4,204,271 |
| Senior Vice President and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Morrissey | $33,239,183 | $12,732,048 | $16,423,307 | +20,507,135 |
| Amy Peterson | 11,146,034 | 4,446,015 | 7,378,846 | +6,700,019 |
| Christopher Senner | 10,648,472 | 4,680,160 | 4,947,631 | +5,968,312 |
| Dana Aftab | 10,547,248 | 3,616,578 | 5,653,142 | +6,930,670 |
| Patrick Haley | 9,021,416 | — | — | — |
| Jeffrey Hessekiel | 8,992,592 | 3,736,716 | 4,562,689 | +5,255,876 |
| Brenda Hefti | 4,204,271 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Morrissey | Director | 2026-05-06 | D | 109,676 | $0 | $0 | Common | Form 4 ↗ |
| Mary C. Beckerle | Director | 2026-05-07 | A | 3,856 | 23 | 89,613 | Common | Form 4 ↗ |
| George Poste | Director | 2026-05-07 | D | 60,000 | 46 | 2,742,600 | Common | Form 4 ↗ |
| Mary C. Beckerle | Director | 2026-05-07 | D | 7,712 | 48 | 373,646 | Common | Form 4 ↗ |
| Maria C. Freire | Director | 2026-05-07 | D | 20,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maria C. Freire | Director | 2026-05-07 | A | 20,634 | 20 | 407,934 | Common | Form 4 ↗ |
| Mary C. Beckerle | Director | 2026-05-07 | D | 3,856 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maria C. Freire | Director | 2026-05-07 | D | 20,634 | 46 | 949,164 | Common | Form 4 ↗ |
| Christopher Senner | EVP and CFO | 2026-05-15 | D | 40,892 | 51 | 2,089,581 | Common | Form 4 ↗ |
| Dana Aftab | EVP, Research and Development | 2026-05-15 | D | 30,578 | 51 | 1,562,536 | Common | Form 4 ↗ |
| Michael Morrissey | Director | 2026-05-15 | D | 124,047 | 0 | 0 | Common | Form 4 ↗ |
| Michael Morrissey | Director | 2026-05-15 | A | 124,047 | 0 | 0 | Common | Form 4 ↗ |
| Michael Morrissey | Director | 2026-05-15 | D | 128,497 | 51 | 6,566,197 | Common | Form 4 ↗ |
| Christopher Senner | EVP and CFO | 2026-05-15 | D | 34,901 | 50 | 1,745,050 | Common | Form 4 ↗ |
| Patrick Haley | EVP, Commercial | 2026-05-15 | D | 33,265 | 51 | 1,699,842 | Common | Form 4 ↗ |
| Brenda Hefti | SVP and General Counsel | 2026-05-15 | D | 6,411 | 51 | 327,602 | Common | Form 4 ↗ |
| Brenda Hefti | SVP and General Counsel | 2026-05-15 | D | 6,625 | 50 | 332,641 | Common | Form 4 ↗ |
| Patrick Haley | EVP, Commercial | 2026-05-20 | D | 32,110 | 50 | 1,599,399 | Common | Form 4 ↗ |
| Dana Aftab | EVP, Research and Development | 2026-05-26 | D | 43,451 | 50 | 2,187,758 | Common | Form 4 ↗ |
| Stelios Papadopoulos | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Tomas J. Heyman | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Maria C. Freire | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Mary C. Beckerle | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Julie A. Smith | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Robert L. Oliver, Jr | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Jack L. Wyszomierski | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| George Poste | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| David E. Johnson | Director | 2026-05-27 | A | 19,133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sue Gail Eckhardt | Director | 2026-05-27 | A | 8,367 | 0 | 0 | RSU | Form 4 ↗ |
| Sue Gail Eckhardt | Director | 2026-06-01 | D | 9,812 | 50 | 491,974 | Common | Form 4 ↗ |
| Jack L. Wyszomierski | Director | 2026-06-01 | D | 3,925 | 51 | 198,409 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Morrissey | RSU | 2025-02-26 | — | — | 184,909 | — | $6,939,635 |
| Christopher Senner | OTHER | 2025-03-31 | — | 170,009 | — | — | 4,267,226 |
| Dana Aftab | RSU | 2025-02-26 | — | — | 49,209 | — | 1,846,814 |
| Dana Aftab | RSU | 2025-10-08 | — | — | 50,673 | — | 1,958,005 |
| Brenda Hefti | RSU | 2025-02-26 | — | — | 14,774 | — | 554,468 |
| Michael Morrissey | PSU | 2025-02-26 | 92,454 | 184,909 | — | 323,590 | 8,797,970 |
| Patrick Haley | RSU | 2025-02-26 | — | — | 47,718 | — | 1,790,857 |
| Brenda Hefti | OTHER | 2025-03-31 | — | 34,533 | — | — | 866,778 |
| Dana Aftab | OTHER | 2025-03-31 | — | 132,819 | — | — | 3,333,757 |
| Christopher Senner | RSU | 2025-02-26 | — | — | 59,648 | — | 2,238,589 |
| Brenda Hefti | RSU | 2025-12-03 | — | — | 30,170 | — | 1,327,782 |
| Patrick Haley | PSU | 2025-02-26 | 23,858 | 47,718 | — | 83,506 | 2,270,422 |
| Christopher Senner | PSU | 2025-02-26 | 29,824 | 59,648 | — | 104,384 | 2,838,052 |
| Dana Aftab | PSU | 2025-02-26 | 24,604 | 49,209 | — | 86,115 | 2,341,364 |
| Patrick Haley | OTHER | 2025-03-31 | — | 159,383 | — | — | 4,000,513 |
| Brenda Hefti | PSU | 2025-02-26 | 7,386 | 14,774 | — | 25,854 | 702,947 |
| Michael Morrissey | OTHER | 2025-03-31 | — | 589,719 | — | — | 14,801,947 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Morrissey | $6,939,635 | $8,797,970 | $0 | 55.9% |
| Christopher Senner | 2,238,589 | 2,838,052 | 0 | 55.9% |
| Dana Aftab | 3,804,819 | 2,341,364 | 0 | 38.1% |
| Brenda Hefti | 1,882,250 | 702,947 | 0 | 27.2% |
| Patrick Haley | 1,790,857 | 2,270,422 | 0 | 55.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Senner | RSU | 61,591 | — | $2,684,136 |
| Patrick Haley | RSU | 61,876 | — | 2,696,556 |
| Michael Morrissey | RSU | 156,593 | — | 6,824,323 |
| Dana Aftab | RSU | 63,350 | — | 2,760,793 |
| Dana Aftab | RSU | 47,513 | — | 2,070,617 |
| Michael Morrissey | RSU | 184,909 | — | 8,058,334 |
| Michael Morrissey | RSU | 241,670 | — | 10,531,979 |
| Patrick Haley | RSU | 63,350 | — | 2,760,793 |
| Patrick Haley | RSU | 47,513 | — | 2,070,617 |
| Michael Morrissey | RSU | 548,073 | — | 23,885,021 |
| Dana Aftab | RSU | 52,053 | — | 2,268,470 |
| Michael Morrissey | Option | 494,700 | 21.31 | — |
| Michael Morrissey | RSU | 236,614 | — | 10,311,638 |
| Patrick Haley | RSU | 39,860 | — | 1,737,099 |
| Michael Morrissey | RSU | 589,719 | — | 25,699,954 |
| Christopher Senner | RSU | 170,009 | — | 7,408,992 |
| Christopher Senner | RSU | 66,487 | — | 2,897,503 |
| Christopher Senner | RSU | 42,708 | — | 1,861,215 |
| Dana Aftab | RSU | 14,873 | — | 648,165 |
| Brenda Hefti | RSU | 7,386 | — | 321,882 |
| Brenda Hefti | RSU | 5,775 | — | 251,675 |
| Michael Morrissey | RSU | 181,253 | — | 7,899,006 |
| Patrick Haley | RSU | 159,383 | — | 6,945,911 |
| Christopher Senner | RSU | 149,474 | — | 6,514,077 |
| Patrick Haley | RSU | 139,508 | — | 6,079,759 |
| Dana Aftab | RSU | 132,819 | — | 5,788,252 |
| Dana Aftab | RSU | 119,578 | — | 5,211,209 |
| Michael Morrissey | RSU | 92,454 | — | 4,029,145 |
| Christopher Senner | RSU | 82,121 | — | 3,578,833 |
| Michael Morrissey | RSU | 67,604 | — | 2,946,182 |
| Christopher Senner | RSU | 59,648 | — | 2,599,460 |
| Dana Aftab | RSU | 50,673 | — | 2,208,329 |
| Dana Aftab | RSU | 50,000 | — | 2,179,000 |
| Dana Aftab | RSU | 49,209 | — | 2,144,528 |
| Patrick Haley | RSU | 47,718 | — | 2,079,550 |
| Brenda Hefti | RSU | 34,533 | — | 1,504,948 |
| Dana Aftab | RSU | 34,166 | — | 1,488,954 |
| Brenda Hefti | RSU | 30,170 | — | 1,314,809 |
| Christopher Senner | RSU | 29,824 | — | 1,299,730 |
| Dana Aftab | RSU | 24,604 | — | 1,072,242 |
| Patrick Haley | RSU | 23,858 | — | 1,039,732 |
| Christopher Senner | RSU | 18,997 | — | 827,889 |
| Patrick Haley | RSU | 17,679 | — | 770,451 |
| Brenda Hefti | RSU | 14,789 | — | 644,505 |
| Brenda Hefti | RSU | 14,774 | — | 643,851 |
| Brenda Hefti | RSU | 14,272 | — | 621,974 |
| Brenda Hefti | RSU | 10,704 | — | 466,480 |
Provide market-competitive compensation that attracts, motivates and retains executive officers who present the skills, expertise, and experience necessary to grow our business and sustain our mission; Balance shorter- and longer-term incentives and incorporate compensation elements that reward both service over time and performance; Align our executive officers compensation with the interests of our stockholders; and Reward our executive officers for success in achieving our corporate goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-26 | 163,104,135 | 43,156,553 | 329,618 | 78.95% | Passed |
| 2025 | 2025-05-28 | 218,948,303 | 6,761,611 | 288,538 | 96.88% | Passed |
| 2024 | 2024-05-30 | 226,652,255 | 9,785,746 | 467,134 | 95.67% | Passed |
| 2023 | 2023-05-31 | 212,824,174 | 42,820,366 | 1,171,837 | 82.87% | Passed |
| 2022 | 2022-05-25 | 243,569,589 | 6,255,051 | 1,052,298 | 97.09% | Passed |
| 2021 | 2021-05-26 | 228,983,027 | 3,839,053 | 579,408 | 98.11% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-26 | 78.95%a |
| 2025 | 2025-05-28 | 96.88%b |
| 2024 | 2024-05-30 | 95.67%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against the proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as votes against this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 81 : 1 |
|---|---|
| CEO total compensation | $33,239,183 |
| Median employee compensation | $410,693 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stelios Papadopoulos, Ph.DIndependent · Board Chair · Audit · Compensation | $137,750 | $417,991 | — | $0 | — | $555,741 |
| Julie A. SmithIndependent · Audit · Compensation (Chair) | 100,000 | 417,991 | — | 0 | 2,500 | 520,491 |
| Jack L. WyszomierskiIndependent · Audit (Chair) | 102,000 | 417,991 | — | 0 | — | 519,991 |
| Maria C. Freire, Ph.DIndependent | 97,000 | 417,991 | — | 0 | 2,500 | 517,491 |
| Tomas J. HeymanIndependent | 97,000 | 417,991 | — | 0 | 2,500 | 517,491 |
| George Poste, DVM, Ph.D., FRSIndependent | 97,000 | 417,991 | — | 0 | — | 514,991 |
| Mary C. Beckerle, Ph.DIndependent · Governance · Research & Development · Risk | 93,000 | 417,991 | — | 0 | 2,500 | 513,491 |
| David E. JohnsonIndependent · Audit | 87,000 | — | 417,709 | 0 | 2,500 | 507,209 |
| S. Gail Eckhardt, M.DIndependent · Compensation · Research & Development | 84,000 | 417,991 | — | 0 | 2,500 | 504,491 |
| Robert L. Oliver, JrIndependent · Compensation | 84,000 | 417,991 | — | 0 | — | 501,991 |
| Michael M. Morrissey, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 40,000 / 35,000 |
| Stock ownership guideline | 5x annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $978,750 |
| Equity awards (grant-date value) | $3,761,919 |
| All other compensation | $15,000 |
| Total cost of the board | $4,755,669 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Exelixis, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Exelixis, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 4 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 7 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 8 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 9 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 10 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | NovoCure Limited | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 14 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 15 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 16 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 17 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Alkermes plc | 130% | PSU 53 · RSU 24 · Options 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Incyte Corporation | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Ionis Pharmaceuticals, Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| NovoCure Limited | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutics, Inc. | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics Corporation | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Morrissey | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 2 | Section 01, Amy Peterson | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 11,146,034. Filing ↗machine: span 2743051–2743061 |
| 3 | Section 01, Christopher Senner | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 10,648,472. Filing ↗machine: r5 · c10 · span 2672994–2673004 |
| 4 | Section 01, Dana Aftab | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 10,547,248. Filing ↗machine: span 2691112–2691122 |
| 5 | Section 01, Patrick Haley | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 9,021,416. Filing ↗machine: r11 · c10 · span 2709603–2709612 |
| 6 | Section 01, Jeffrey Hessekiel | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 8,992,592. Filing ↗machine: span 2723440–2723449 |
| 7 | Section 01, Brenda Hefti | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Summary Compensation Table”. As printed: 4,204,271. Filing ↗machine: span 2717011–2717020 |
| 8 | Section 03, Michael Morrissey RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r2 · c1 · span 2507301–2507308 |
| 9 | Section 03, Christopher Senner OTHER | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t237 · r3 · c1 · span 2559596–2559603 |
| 10 | Section 03, Dana Aftab RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r4 · c3 · span 2511617–2511623 |
| 11 | Section 03, Dana Aftab RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t259 · r17 · c10 · span 2980753–2980759 |
| 12 | Section 03, Brenda Hefti RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r6 · c3 · span 2515361–2515367 |
| 13 | Section 03, Michael Morrissey PSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r2 · c1 · span 2507301–2507308 |
| 14 | Section 03, Patrick Haley RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r5 · c1 · span 2512659–2512665 |
| 15 | Section 03, Brenda Hefti OTHER | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t237 · r6 · c1 · span 2562769–2562775 |
| 16 | Section 03, Dana Aftab OTHER | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t237 · r4 · c1 · span 2560650–2560657 |
| 17 | Section 03, Christopher Senner RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r3 · c1 · span 2508923–2508929 |
| 18 | Section 03, Brenda Hefti RSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t259 · r28 · c10 · span 3039562–3039568 |
| 19 | Section 03, Patrick Haley PSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r5 · c1 · span 2512659–2512665 |
| 20 | Section 03, Christopher Senner PSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r3 · c1 · span 2508923–2508929 |
| 21 | Section 03, Dana Aftab PSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r4 · c3 · span 2511617–2511623 |
| 22 | Section 03, Patrick Haley OTHER | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t237 · r5 · c1 · span 2561706–2561713 |
| 23 | Section 03, Brenda Hefti PSU | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t233 · r6 · c3 · span 2515361–2515367 |
| 24 | Section 03, Michael Morrissey OTHER | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t237 · r2 · c1 · span 2558535–2558542 |
| 25 | Section 07, pay ratio | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “CEO Pay Ratio”. As printed: 81 : 1. Filing ↗ |
| 26 | Section 08, Stelios Papadopoulos, Ph.D | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 555,741. Filing ↗machine: t108 · r8 · c5 · span 1086052–1086059 |
| 27 | Section 08, Julie A. Smith | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 520,491. Filing ↗machine: t108 · r10 · c5 · span 1094783–1094790 |
| 28 | Section 08, Jack L. Wyszomierski | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 519,991. Filing ↗machine: t108 · r11 · c5 · span 1099143–1099150 |
| 29 | Section 08, Maria C. Freire, Ph.D | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 517,491. Filing ↗machine: t108 · r4 · c5 · span 1068620–1068627 |
| 30 | Section 08, Tomas J. Heyman | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 517,491. Filing ↗machine: t108 · r5 · c5 · span 1072966–1072973 |
| 31 | Section 08, George Poste, DVM, Ph.D., FRS | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 514,991. Filing ↗machine: t108 · r9 · c5 · span 1090419–1090426 |
| 32 | Section 08, Mary C. Beckerle, Ph.D | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 513,491. Filing ↗machine: t108 · r2 · c5 · span 1059912–1059919 |
| 33 | Section 08, David E. Johnson | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 507,209. Filing ↗machine: t108 · r6 · c5 · span 1077313–1077320 |
| 34 | Section 08, S. Gail Eckhardt, M.D | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 504,491. Filing ↗machine: t108 · r3 · c5 · span 1064268–1064275 |
| 35 | Section 08, Robert L. Oliver, Jr | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 501,991. Filing ↗machine: t108 · r7 · c5 · span 1081673–1081680 |
| 36 | Section 08, Michael M. Morrissey, Ph.D | DEF 14A | 2026-04-15 | 0000939767-26-000046 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 37 | Section 02, Michael Morrissey 2026-05-06 | Form 4 | 2026-05-08 | 0000939767-26-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mary C. Beckerle 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, George Poste 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mary C. Beckerle 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Maria C. Freire 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Maria C. Freire 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Mary C. Beckerle 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Maria C. Freire 2026-05-07 | Form 4 | 2026-05-08 | 0000939767-26-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Christopher Senner 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Dana Aftab 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Michael Morrissey 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Michael Morrissey 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Michael Morrissey 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Christopher Senner 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Patrick Haley 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Brenda Hefti 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Brenda Hefti 2026-05-15 | Form 4 | 2026-05-19 | 0000939767-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Patrick Haley 2026-05-20 | Form 4 | 2026-05-22 | 0000939767-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Dana Aftab 2026-05-26 | Form 4 | 2026-05-28 | 0000939767-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Stelios Papadopoulos 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Tomas J. Heyman 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Maria C. Freire 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Mary C. Beckerle 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Julie A. Smith 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Robert L. Oliver, Jr 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Jack L. Wyszomierski 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, George Poste 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, David E. Johnson 2026-05-27 | Form 4 | 2026-05-29 | 0000902664-26-002641 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Sue Gail Eckhardt 2026-05-27 | Form 4 | 2026-05-29 | 0000939767-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Sue Gail Eckhardt 2026-06-01 | Form 4 | 2026-06-03 | 0000939767-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Jack L. Wyszomierski 2026-06-01 | Form 4 | 2026-06-03 | 0000939767-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 06, 2026 vote | Form 8-K | 2026-05-29 | 0000939767-26-000074 | Item 5.07 · say-on-pay result. As reported: 78.95% (votes for as printed: 163,104,135). Filing ↗ |
| 69 | Section 06, 2025 vote | Form 8-K | 2025-06-02 | 0000939767-25-000097 | Item 5.07 · say-on-pay result. As reported: 96.88% (votes for as printed: 218,948,303). Filing ↗ |
| 70 | Section 06, 2024 vote | Form 8-K | 2024-06-03 | 0000939767-24-000081 | Item 5.07 · say-on-pay result. As reported: 95.67% (votes for as printed: 226,652,255). Filing ↗ |
| 71 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 72 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 73 | Section 09b board cost (computed) | Computed | — | computed | Cash 978,750 + equity 3,761,919 + all other 15,000 = 4,755,669, summed across the director compensation table rows.machine: formula: Σ = 4,755,669 |
| 74 | Exelixis, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 75 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 76 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 77 | Halozyme Therapeutics, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 78 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 79 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 80 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 81 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 82 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 83 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 84 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 85 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 86 | NovoCure Limited, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001645113-26-000033 | CEO total compensation as printed in NovoCure Limited's own proxy. As printed: 13,198,354. Filing ↗machine: r6 · c48 · span 880842–880852 |
| 87 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 88 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 89 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 90 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 91 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include Exelixis, Inc.. Filing ↗ |
| 92 | Section 10a, Halozyme Therapeutics reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 93 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 94 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 95 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 96 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 97 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 98 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 99 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 100 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Exelixis, Inc.. Filing ↗ |
| 101 | Section 10a, NovoCure Limited reciprocity | DEF 14A | — | 0001645113-26-000033 | NovoCure Limited names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 102 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 103 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Exelixis, Inc.. Filing ↗ |
| 104 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc. names Exelixis, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |